January 9, 2025

FDA Approves New, Once-a-Day CFTR Modulator for People With Cystic Fibrosis 

The FDA has approved a new triple-combination modulator, Alyftrek, for people with cystic fibrosis ages 6 years and older who have a mutation that is eligible for Trikafta or one of 31 rare mutations that had not been approved previously for a modulator.  

Read the announcement »

Trikafta Approved for People With CF Ages 2 Years and Older With Certain Mutations   

Last month, the FDA approved the expansion of Trikafta to additional people with cystic fibrosis ages 2 years and older who have certain rare mutations. Although this approval affects a very small number of people, it is another important step in making sure that everyone with CF has a treatment for the underlying cause of their disease.   

See the approved mutations »

Join Us for a Conversation With Foundation Leadership 

Join our President and CEO, Michael Boyle, MD, our Executive Vice President and Chief Operating and Financial Officer, Irena Barisic, and other Foundation leaders virtually January 22 at 8 p.m. EST/5 p.m. PST for our fifth National Annual Meeting. After short opening remarks, you will have the chance to ask our leadership your questions about what’s ahead for 2025. We can’t wait to see you there!  

Save my seat »

Connect With Adults With CF Through Small Group Discussions 

Life with cystic fibrosis comes with unique experiences and challenges — connect virtually with other adults who understand the ups and downs that come with CF through CF Circles. These topic-based, small-group discussions provide the opportunity to create connections and share your story in a supportive environment. Upcoming sessions include: 

• January 14: Life Without Modulators
• February 25: Sexual Health
• March 25: Living Longer With CF